Summary

• The company cannot recommend any practices, procedures, or usage that deviate from the approved labeling.
• Please refer to the local labeling for information on drug interactions with IMAAVY.

COMPANY CORE DATA SHEET

Pharmacokinetic Interactions

Effect of IMAAVY on Other Drugs

• Concomitant use of IMAAVY may reduce systemic exposure of medications that bind to human neonatal Fc receptor (FcRn) (eg, immunoglobulin G [IgG] products, IgG-based monoclonal antibodies, antibody derivates containing the human Fc domain of the IgG subclass, or Fc fusion proteins). In clinical drug-interaction studies in healthy participants, nipocalimab reduced the systemic exposure (maximum concentration [C_max] and area under the curve [AUC]) of fremanezumab and etanercept.¹ 
• When concomitant long-term use of such medications is essential for patient care, closely monitor for reduced effectiveness of such medications and consider discontinuing IMAAVY or using alternative therapies.¹ 
• When coadministered with fremanezumab in healthy participants, IMAAVY reduced C_max and AUC (systemic exposure) of fremanezumab by 42% and 66%, respectively. When IMAAVY was administered 14 days after fremanezumab dosing, C_max was not altered but AUC was reduced by 53%.¹ 
• When coadministered with etanercept in healthy participants, IMAAVY reduced etanercept C_max by ~8% and AUC by ~28%.¹ 

Effect of Other Drugs on IMAAVY

• In a clinical drug-interaction study in healthy participants evaluating the effect of hydroxychloroquine (HCQ) on IMAAVY pharmacodynamics, IgG reduction following IMAAVY administration was comparable with and without HCQ coadministration.¹

Cytochrome P450 Substrates

• Nipocalimab is not metabolized by cytochrome P450 enzymes; therefore, interactions with concomitant medications that are substrates, inducers, or inhibitors of cytochrome P450 enzymes are unlikely.¹ 

Literature Search

A literature search of MEDLINE^®, EMBASE^®, BIOSIS Previews^®, and DERWENT^® (and/or other resources, including internal/external databases) conducted on 16 October 2025 did not identify any relevant citations pertaining to this topic.